We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03721679
Recruitment Status : Terminated (Recruiting target patients is intermittent making it impracticable to enroll the required study sample. The administrative responsibilities have been met with extraordinary challenges. Current funding does not match the incurring costs.)
First Posted : October 26, 2018
Last Update Posted : February 1, 2021
Sponsor:
Collaborators:
Chevy Chase Healthcare, Chevy Chase MD
Mt. Sinai School of Medicine, New York, New York
Bay Hematology Oncology PA, Easton MD
Information provided by (Responsible Party):
Oncovir, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
Recruitment Status : Terminated
Actual Primary Completion Date : January 26, 2021
Actual Study Completion Date : January 26, 2021
Publications of Results: